英科医疗
(300677)
| 流通市值：169.53亿 | | | 总市值：238.67亿 |
| 流通股本：4.65亿 | | | 总股本：6.55亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,913,439,043.41 | 2,493,933,645.56 | 9,523,317,123.49 | 7,098,445,816 |
| 营业收入 | 4,913,439,043.41 | 2,493,933,645.56 | 9,523,317,123.49 | 7,098,445,816 |
| 二、营业总成本 | 4,407,224,021.98 | 2,227,922,943.92 | 8,106,201,641.65 | 6,392,765,528 |
| 营业成本 | 3,722,998,252.37 | 1,891,377,146.12 | 7,272,347,663.47 | 5,506,101,002 |
| 税金及附加 | 51,146,652.78 | 28,621,027.7 | 65,551,156.4 | 46,960,301 |
| 销售费用 | 134,603,593.38 | 71,185,277.78 | 288,443,843.68 | 202,654,119 |
| 管理费用 | 292,139,371.7 | 149,369,194.14 | 518,139,926.38 | 378,905,763 |
| 研发费用 | 203,842,179.9 | 99,551,616.56 | 398,344,414.56 | 293,282,144 |
| 财务费用 | 2,493,971.85 | -12,181,318.38 | -436,625,362.84 | -35,137,801 |
| 其中:利息费用 | 190,204,566.97 | 95,394,054.88 | 308,037,023.74 | 207,733,594 |
| 其中:利息收入 | 237,250,957.95 | 131,053,333.02 | 533,356,405.99 | 389,245,660 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 228,448,036.21 | 72,441,131.1 | 279,767,035.6 | 32,357,675 |
| 加:投资收益 | 51,058,982.5 | 24,266,443.12 | 63,176,605.34 | 49,350,964 |
| 资产处置收益 | -11,052.2 | -16,469.02 | 224,360.4 | 15,891 |
| 资产减值损失(新) | -9,679,120.15 | -953,122.65 | -109,052,505.2 | -1,610,083 |
| 信用减值损失(新) | 220,801.19 | 1,492,874.31 | -32,779,876.77 | -34,707,611 |
| 其他收益 | 40,169,195.07 | 33,524,964.94 | 58,372,443.32 | 34,765,544 |
| 四、营业利润 | 816,421,864.05 | 396,766,523.44 | 1,676,823,544.53 | 785,852,668 |
| 加:营业外收入 | 1,210,380.04 | 588,408.76 | 2,541,261.33 | 5,032,460 |
| 减:营业外支出 | 5,591,742.45 | 529,041.78 | 70,446,789.13 | 11,049,975 |
| 五、利润总额 | 812,040,501.64 | 396,825,890.42 | 1,608,918,016.73 | 779,835,153 |
| 减:所得税费用 | 85,415,281.65 | 35,452,972.69 | 117,228,963.13 | 80,051,223 |
| 六、净利润 | 726,625,219.99 | 361,372,917.73 | 1,491,689,053.6 | 699,783,930 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 726,625,219.99 | 361,372,917.73 | 1,491,689,053.6 | 699,783,930 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 710,439,983.93 | 352,721,895.21 | 1,465,476,194.01 | 687,466,463 |
| 少数股东损益 | 16,185,236.06 | 8,651,022.52 | 26,212,859.59 | 12,317,467 |
| 扣除非经常损益后的净利润 | 400,201,229 | 246,606,613.51 | 1,167,265,063.93 | 600,509,165 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.12 | 0.55 | 2.26 | 1.05 |
| (二)稀释每股收益 | 1.12 | 0.55 | 2.26 | 1.05 |
| 八、其他综合收益 | -509,610.39 | -5,676,841.42 | -5,904,455.53 | 5,928,165 |
| 归属于母公司股东的其他综合收益 | -509,610.39 | -5,676,841.42 | -5,904,455.53 | 5,928,165 |
| 九、综合收益总额 | 726,115,609.6 | 355,696,076.31 | 1,485,784,598.07 | 705,712,095 |
| 归属于母公司股东的综合收益总额 | 709,930,373.54 | 347,045,053.79 | 1,459,571,738.48 | 693,394,628 |
| 归属于少数股东的综合收益总额 | 16,185,236.06 | 8,651,022.52 | 26,212,859.59 | 12,317,467 |
| 公告日期 | 2025-08-29 | 2025-04-29 | 2025-04-24 | 2024-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |